23 June 2022 
EMA/CHMP/592350/2022  
Human Medicines Evaluation Division 
Statement indicating compliance with the agreed 
completed paediatric investigation plan 
Medicinal product  
Forxiga/dapagliflozin 
Edistride/dapagliflozin 
See Annex A  
Pharmaceutical form(s): 
See Annex A 
Strength(s): 
Route(s) of administration: 
See Annex A 
Packaging and package size(s):  See Annex A 
See Annex A 
Number(s) in the Community 
Register of Medicinal Products: 
Marketing authorisation holder (MAH): 
Name and address of the MAH:  AstraZeneca AB 
151 85 Sodertralja 
Sweden 
Procedure  
Procedure number: 
EMEA/xxxx/WS/2284 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
-the development of this product has complied with all measures in the agreed paediatric investigation 
plan PIP/0086/2020. All studies in the agreed paediatric investigation plan PIP/0086/2020 were 
conducted after the entry into force of that Regulation, 
-the Summary of Product Characteristics adopted by CHMP already reflected the results of studies 
conducted in compliance with this agreed paediatric investigation plan. 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
